Review Article

Interleukin-37: The Effect of Anti-Inflammatory Response in Human Coronary Artery Endothelial Cells

Xianfeng Yan,1 Bin Xie,1 Guihai Wu,1 Jing Hu,2 Di Wang,3 Xiangna Cai,4, and Jilin Li1

1Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China
2Department of Cardiology, Jiangxi Provincial People’s Hospital, Nanchang, Jiangxi 330006, China
3Department of Dermatovenereology, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China
4Department of Plastic Surgery, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, China

Correspondence should be addressed to Xiangna Cai; caixiangna@126.com and Jilin Li; lijilin@126.com

Received 2 May 2018; Revised 7 September 2018; Accepted 6 November 2018; Published 8 January 2019

Academic Editor: Daniela Novick

Copyright © 2019 Xianfeng Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Interleukin-37 (IL-37) is unique in the IL-1 family since it broadly suppresses innate immunity and elevates in humans with inflammatory and autoimmune diseases. IL-37 shows definite groups and transcripts for human IL37 gene, but it is still not completely understood the effect and mechanisms of inflammatory response in endothelial cells. It is well accepted that endothelial dysfunction caused by inflammation is a key initiating event in atherosclerotic plaque formation, which leads to the occurrence and development of the cardiovascular adverse events in clinical since the inflammatory responses of endothelial cells could induce and enhance the deposition of extensive lipid and the formation of atherosclerotic plaque in the intima. Thus, it is essential to investigate the role and potential mechanisms in endothelial inflammatory response to prevent the formation and development of many cardiovascular diseases including atherosclerosis. So far, the recent studies have revealed that IL-37 is able to inhibit inflammatory response by suppressing the TLR2-NF-κB-ICAM-1 pathway intracellularly in human coronary artery endothelial cells (HCAECs). Further, the role of IL-37 may be related to the IL-18 pathway extracellularly and involved in the adhesion and transmigration of neutrophils in HCAECs.

1. Introduction

IL-37 (formerly known as the interleukin-1 family member 7 or IL-1F7 [1, 2]) distinguishes itself from most other anti-inflammatory cytokines by exerting functions that inhibit the responses of a broad spectrum of inflammatory assaults, including proinflammatory cytokines, such as IL-1b, TNF, and TLRs [3–5]. IL-37 has three independent groups and five transcripts [6–8] for the human IL37 gene (IL-37a-e) [9–12]. In vitro, the expression of IL-37 in macrophages or epithelial cells was shown to greatly inhibit constitutive or induced production of several major proinflammatory cytokines, such as IL-1α, IL-1β, IL-6, MIP-2, and TNF [4, 13]. In vivo, IL-37 protects mice from LPS-induced shock, chemical-induced colitis, and hepatitis [4, 14–16]. Nonetheless, the exact function of IL-37 has remained unapproached.

It is worth noting that transgenic mice expressing the human IL-37 gene have elucidated the anti-inflammatory properties of this cytokine [4]. Transgenic mice expressing human IL-37 (IL37-tg) mice exhibit a prominent protection from myocardial ischemia [4, 14]. IL37-tg mice that suffered from coronary artery ligation had prominently reduced infarct size and improved left ventricular function compared to similarly challenged WT mice. Mice with transgenic expression of IL-37 were protected from lipopolysaccharide-induced shock and exhibited prominent improved endothelial dysfunction after treating with LPS. The previous studies had revealed that the expression of IL-37 in macrophages or epithelial cells almost entirely inhibited production of proinflammatory cytokines, whereas the mass of these cytokines increased with silencing of endogenous IL-37 in human blood cells [17]. And recent research showed that IL-37 is able to offer an anti-inflammatory microenvironment...
in the aging bone marrow [18]. Thus, IL-37 emerges as a natural inhibitor of inflammatory responses.

As an IL-1 family member, a growing number of the recent reports reveal that IL-37 plays a crucial role in limiting innate inflammation as well as inflammatory action. For example, the recent study illustrates that IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells [19]. Besides, IL-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice [20]. Increased level of IL-37 in patients with Graves’ disease (GD) is associated with disease activity, and it plays a protective role against inflammatory effect in GD by inhibiting the production of proinflammatory cytokines [21]. Reducing endogenous IL-37 in human cells reveals that IL-37 limits the production of cytokines induced by IL-1 and Toll-like receptors (TLR) [4] as well as urate crystals [22].

Furthermore, IL-37 plays a critical role in suppressing cardiodepressant cytokines, while it improves LV function in aging mice during endotoxemia through suppression of myocardial production of MCP-1 and cardiodepressant cytokines [23]. Circulating levels of pro-/anti-inflammatory cytokines, including IL-37, may be related to the pathogenesis of atherosclerosis in patients with either acute coronary syndrome or stable coronary artery disease [24]. Our group found that IL-37 may be involved in leukocytic inflammation in acute ST-segment elevation myocardial infarction (STEMI) after PCI [25]. Since the anti-inflammatory response is inhibited in patient with STEMI, the expression of IL-37 is lower in the STEMI than in the healthy [26, 27].

It is worth mentioning that IL-37 exerts inhibitory effect on neuroinflammation in new frontiers. Neuroinflammation induced by the activation of brain nociceptors and neurons is related to mast cells (MCs) which could lead to the secretion of proinflammatory IL-1 family members and TNF. The IL-1 family members and MC-derived TNF which contribute to neuroinflammation by mediating the sensitization of meningeal nociceptors could be inhibited by IL-37 [28]. Similarly, IL-37 also exerts inhibitory effect on inflammation of fibromyalgia. The inflammation of fibromyalgia may derive from the increase in reactivity of central neurons with increased sensitivity localized mainly in the CNS. MCs could release proinflammatory cytokines, chemokines, and chemical mediators when they are involved in the inflammation of fibromyalgia, and the level of TNF induced by MCs elevates in fibromyalgia. At the same time, IL-37 could inhibit the inflammation response of IL-1 family members and TNF in fibromyalgia [29]. Moreover, IL-37 could inhibit macrophage response and its accumulation and reduce the cytokines that mediate inflammatory diseases since IL-37 inhibits innate and adaptive immunities. IL-37 binds IL-18R alpha chain and reduces the production of TNF and inflammatory IL-1 family members induced by MCs since MC activation could contribute to adaptive immunity and inflammation [30]. A recent report manifests that MCs may be activated via the TLR-dependent pathway controlled by MyD88, which could be inhibited by IL-37 [31]. Therefore, at this level, IL-37 is involved and inhibits the MC-mediated adaptive immune and inflammatory responses.

However, the anti-inflammatory effects of IL-37 differ from other anti-inflammatory cytokines such as IL-10 and TGF-beta. On one hand, IL-37 exerts anti-inflammatory responses by suppressing the phosphorylation of NF-xB via MyD88 or N-MyD88 signaling pathway intracellularly. On the other hand, IL-37 also inhibits the formation of functional complex of IL-18Ra/IL-18/IL-18Rβ by capturing IL-18Ra on the cell surface extracellularly, to indirectly inhibit the biological activity of IL-18 [32]. In addition, it is also involved in phosphorylation of NF-xB when IL-37 exerts anti-inflammatory responses extracellularly. IL-37 binds to TLR-8 and then inhibits the phosphorylation of NF-xB by regulating signal molecules such as STAT3, p62, and PTEN. So, the forming the functional complex of IL-37/IL-18Ra/- TIR-8 on the cell surface interferes with the function of a typical TIR domain, which hinders the downstream signal transduction of TIRs, including NF-xB [33, 34]. However, the anti-inflammatory function of IL-10 is not only related to the inhibition of NF-xB but also involved in the IL-10-Stat3 signaling. Stat3 is anti-inflammatory for IL-10 while proinflammatory for IL-6 signaling since it induces the expression of Socs3 that regulates various cytokine signaling pathways including IL-6 [35]. It is worth mentioning that the nuclear activity of IL-37 is similar to TGF-β. TGF-β binds to TGF-β receptor II (TGF-βRII) triggering the kinase activity of the cytoplasmic domain, which in turn leads to nuclear translocation of Smad molecules and transcription of target genes [36]. However, the presence of the cytokines such as IL-4, 6, 9, 10, and 17 and IFN-γ and the interaction of immune cells such as Th17 cells and CD8+ T cells are indispensable when TGF-β plays a major role under inflammatory conditions [37]. So, this is the biggest difference between TGF and IL-37 in terms of anti-inflammatory.

2. **IL-37 Is a “Dual Function” Anti-Inflammatory Cytokine**

Interestingly, IL-37 is regarded as a “dual function” anti-inflammatory cytokine [38]. On one hand, the translocation of IL-37 to the nucleus requires Smad3 when it takes a biological effect [39]. Caspase-1 processing is required for maturation of the intracellular IL-37 precursor and for the translocation of the cytokine to the nucleus [40]. Then IL-37 translocates to the nucleus and then comes into being a complex of Smad3 and IL-37, which induces the nuclear activity of IL-37 [13]. IL-37 interacted intracellularly with Smad3 and IL-37-expressing cells, and transgenic mice exhibited less cytokine inhibition when endogenous Smad3 was depleted. IL-37 is stored intracellularly and rapidly released when the cell encounters an inflammatory assault, which may combat inflammation in a time-efficient manner without recruiting de novo synthesis. Thus, the intracellular way enables IL-37 to mediate anti-inflammatory actions effectively and briskly. On the other hand, the IL-37 precursor is exported from the cell into the extracellular space to take a series of biological effects. IL-37 is biologically active when released into the extracellular space since neutralizing antibodies did not reverse the anti-inflammatory properties in IL-37g mice [40]. Thus, in this regard, IL-37 is termed...
IL-37 is a “dual function” anti-inflammatory cytokine. IL-37 exerts anti-inflammatory responses beginning with the nuclear activity intracellularly. IL-37 can recruit Smad3 in the cytoplasm and then comes into being a complex of Smad3 and IL-37, which induces the nuclear activity of IL-37. Then the complex translocates into the nucleus to suppress TLR-induced proinflammatory cytokine. Meanwhile, NF-κB may be phosphorylated by IKK in the cytoplasm and then exposures to the nuclear to regulate the transcription of proinflammatory cytokine, such as ICAM-1, VCAM-1, MCP-1, TNF-α, and IL-6. But the phosphorylation of NF-κB can be inhibited by IL-37, which in turn decreases the production of proinflammatory cytokine.

Figure 1: IL-37 is a “dual function” anti-inflammation cytokine. IL-37 exerts anti-inflammatory responses beginning with the nuclear activity intracellularly. IL-37 can recruit Smad3 in the cytoplasm and then comes into being a complex of Smad3 and IL-37, which induces the nuclear activity of IL-37. Then the complex translocates into the nucleus to suppress TLR-induced proinflammatory cytokine. Meanwhile, NF-κB may be phosphorylated by IKK in the cytoplasm and then exposures to the nuclear to regulate the transcription of proinflammatory cytokine, such as ICAM-1, VCAM-1, MCP-1, TNF-α, and IL-6. But the phosphorylation of NF-κB can be inhibited by IL-37, which in turn decreases the production of proinflammatory cytokine.

However, how does IL-37 limit inflammation? The previous studies have shown that IL-37 is a new anti-inflammatory cytokine of the IL-1 family, which regulates the inflammation of specific organ or tissue by independent receptor such as IL-1α and IL-33 [42]. Since IL-37 has been demonstrated in a variety of cell types from different species, including in humans and rodents [4, 44], it is supposed to have an anti-inflammatory function by the downregulation of pro-inflammatory cytokines. The recent studies revealed the potential anti-inflammatory mechanism of IL-37 both extracellularly and intracellularly.

IL-37 is able to inhibit the expression of ICAM-1 following the activation of TLR2 or TLR4 in HCAECs, which is related to the NF-κB pathway [45]. As mentioned above, IL-37 is a “dual function” cytokine that exerts anti-inflammatory effects both intracellularly and extracellularly. NF-κB is prevalent in the cells of the organism, and it is trapped in the cytoplasm when the cells are not stimulated by the inhibitory protein IκB [46]. IκB is degraded by the kinase IKK (IκB kinase) when activated by external stimuli, resulting in the phosphorylation of dissociative NF-κB in the cytoplasm and the exposure to the nuclear localization signal [47], and then transferred to the nucleus and combines with the promoter region of the target gene in the nucleus, which can regulate the transcription of inflammatory cytokine, such as ICAM-1, VCAM-1, MCP-1, TNF-α, and IL-6. But the phosphorylation of NF-κB can be inhibited by IL-37, which in turn decreases the production of proinflammatory cytokine.
Extracellular effect of IL-37 relies on IL-18BP (interleukin 18-binding protein, IL-18BP) [52, 53]. Early studies already revealed that IL-18 binds to its receptor IL-18Rα (IL-18 receptor-α, IL-18Rα) at the cell surface and recruits the IL-18Rβ (IL-18 receptor-β, IL-18Rβ) chain to form a functional complex [32, 54, 55], and it combines with TIR to regulate the transcription of proinflammatory cytokines with the activation of NF-κB. It can prevent the formation of IL-18 functional complex while the IL-37 is combined with IL-18Rα side chain (Figure 2). IL-18BP, a natural inhibitor of IL-18 in humans [56], may bind endogenous IL-37 to upregulate the suppression to IL-18 [52, 57]. However, the affinity of IL-18 with IL-18Rα and IL-18BP is higher than that of IL-37, so IL-37 cannot inhibit the effect of IL-18 effectively [54]. The recent studies have found that the combination of IL-37 and IL-18Rα can recruit TIR-8 to form a functional complex in the cell surface. TIR-8, unlike traditional TIR structures, is able to interfere with the activation of traditional TIR domains [33]. Thus, TIR-8 plays a negative role in the activation of downstream signaling pathways induced by the activation of TLR and IL-1R, including NF-κB domain [34]. Besides, another study has found that knockout of TIR-8 in human and mouse cells increases responsiveness to LPS stimulation and results in the production of a large number of proinflammatory cytokines [58]. IL-37 binds to TIR-8 and then inhibits the phosphorylation of NF-κB by regulating signal molecules such as STAT3, p62, and PTEN [5].

3. IL-37 Exerts Anti-Inflammatory Responses in HCAECS

The IL-37 protein has been shown to be expressed by many tissues and cells of human, such as blood monocytes [59], tissue macrophages, and plasma cells. IL-37 is constitutively induced by TGF-β, TLR agonists [4], beta-defensin-3 in
human keratinocytes [60], or the type II epithelial cell of the human lung [61]. But the abundance of IL-37 transcripts is low in human blood monocytes and dendritic cells (DCs) [62]. Concentrations of IL-37 in the circulation of healthy humans are low (<100 pg/mL) but rise with diseases such as rheumatoid arthritis [63], lupus [64], and preeclampsia [65].

IL-37 exerts anti-inflammatory responses in many types of cells, such as peripheral blood mononuclear cells (PBMCs) [21, 64, 66, 67], renal tubular epithelial cells [68], and HCAECs [45]. A recent study indicated that IL-37 could suppress the production of proinflammatory cytokines in monosodium urate (MSU) crystal-induced inflammatory response in PBMCs [22]. Analogously, an early study suggested that a decreased IL-37 expression in Behçet disease (BD) patients was associated with an increased inflammatory response. Another study found that the increased proinflammatory cytokine production from asthma-induced sputum mononuclear cells was abrogated by the addition of rIL-37 [69]. Interestingly, some researchers found that human renal tubular epithelial cells expressed the IL-18 contraregulatory protein IL-37 as an endogenous control mechanism to reduce inflammation [68]. What is more, an increasing number of the recent studies have shown that IL-37 exerts anti-inflammatory responses in HCAECs.

Moreover, the recombinant forms of IL-37 have been shown to be active in vivo in wild-type (WT) mice that suffered from various models of inflammation. The recent studies have shown that IL-37 could inhibit myocardial inflammation, which protects against cardiac dysfunction during endotoxemia in old mice. LV function was improved since myocardial inflammatory responses to endotoxemia in old mice were suppressed by IL-37, as the result of the attenuation of NF-κB activation and MCP-1 production following LPS stimulation in cardiac microvascular endothelial cells from IL-37tg mice [20]. Similarly, recombinant IL-37 treatment in WT mice also provides protection in models of myocardial infarction [70]. Silencing of IL-37 in human blood monocytes results in a 2- to 3-fold increase in LPS and IL-1b-induced cytokines, suggesting that endogenous IL-37 serves as a natural brake of inflammation [6].

3.1. The Inflammation Response Is Related to the TLR2/4-NF-κB Pathway.

The effect and mechanism of this anti-inflammatory cytokine have been confirmed after the development of increasing recent studies since IL-37 has an anti-inflammation function in a variety of cell types in humans [4, 44]. The previous studies have shown that IL-37 increases substantially in peripheral blood of patients with acute myocardial infarction [71]. What is more, IL-37 is found to ameliorate the inflammatory process in psoriasis by inhibiting the production of proinflammatory cytokine [72]. A recent study reveals that IL-37 may improve the cardiac function in myocardial infarction (MI) mice via inhibition of the inflammatory NF-κB signaling pathway [73]. NF-κB, as a kind of an important nuclear transcription factor, not only plays an important role in inflammation but also relates to myocardial cell apoptosis and myocardial remodeling process after MI [74–76]. In this study, they proved that the inhibition of the NF-κB signaling pathway can improve cardiac function after MI and prognosis since NF-κB can regulate many proinflammatory cytokine transcriptions such as TNFα, IL-6, and monocyte chemotactic protein (MCP-1), which not only cause myocardial cell hypertrophy and apoptosis but also affect the myocardial systolic function leading to ventricular remodeling occurrence and heart failure [77–79].

On the TLR2/4-NF-κB signaling pathway, several previous studies have made some demonstrations about its potential mechanism. An early study that explores the role of S100A1 in hypoxia-induced inflammatory response in cardiomyocytes has demonstrated that S100A1 treatment significantly enhanced IL-37 protein or mRNA level, which in turn could attenuate ROS and phospho-p65 NF-κB levels. Thus, the researchers finally considered that S100A1 could regulate the inflammatory response in H9C2 cells via TLR4/ROS/NF-κB pathway [80–82]. A recent study also further confirmed that IL-37 exerts anti-inflammatory effects via TLR2/4-NF-κB signaling pathway. The study revealed that IL-37 reduced the production of these inflammatory mediators induced by TLR4 whereas knockdown of IL-37 enhanced the induction of these mediators by TLR4. Further, IL-37 not only suppressed inflammatory mediator production induced by the MyD88-dependent TLR2 but also inhibited NF-κB activation induced by TLR2 or TLR4. So, they finally demonstrated that IL-37 suppressed MyD88-mediated responses to reduce inflammatory mediator production via TLR2/4-NF-κB pathway in human aortic valve interstitial cells (AVICs) [19, 83]. Analogously, a recent study has revealed that IL-37 could suppress the inflammatory mediator production in human AVICs via this pathway [84]. The study aimed at making an investigation of the proinflammatory signaling pathway responsible for the anti-inflammatory mechanisms in AVICs suggested that IL-37 suppress AVIC osteogenic responses through inhibition of NF-κB since it had augmented inflammatory response to TLR2/4 agonists [74, 85, 86].

3.2. IL-37 Exerts Anti-Inflammation Response via TLR2-NF-κB-ICAM-1 Pathway in HCAECs.

TLR2/4 activation could increase the IL-37 expression, while the expression of ICAM-1 could be decreased in the mouse coronary microvascular endothelial cells isolated from the IL-37 tg mice, which may be in parallel with the reduction of NF-κB phosphorylation [20]. And our group found that ICAM-1 and NF-κB expression prominently reduced the overexpression of recombinant IL-37b, while this effect is not indicated even abrogated prominently when IL-37 mRNA is silent [45]. Thus, the effect and mechanism of IL-37 on ICAM-1 expression may be due to the decrease of NF-κB.

Some scholars already found that TLR2 activation made the upregulated expression of the inflammatory cytokine ICAM-1 and NF-κB in the inchoate study of HCAECs [87]. They demonstrated that diabetic HCAECs have enhanced inflammatory responses to TLR2 and TLR4 agonists with increased expression of ICAM-1, IL-6, and IL-8. The hyper-inflammary phenotype of diabetic HCAECs is characterized by augmented NF-κB activation in response to TLR2/4 agonists in the absence of altered cellular TLR2/4 levels.
Furthermore, in the recent study, we firstly affirmed that the expression of IL-37 in HCAECs could be regulated when treated with IL-37 transfection plasmid or silent mRNA for 24 h. IL-37 was able to decrease ICAM-1 and NF-κB expression mediated by TLR2 activation in HCAECs, while ICAM-1 and NF-κB expression were increased when IL-37 was knocked out. So, the reduction effect of IL-37 on ICAM-1 expression may be due to the inhibition of activation of NF-κB. And the phosphorylation of NF-κB in intranuclear leads to TLR activation. Translocation of the activated NF-κB into the nucleus to bind to the NF-κB-specific DNA-binding sites, resulting in the regulation of the target genes transcription, such as ICAM-1. Besides, IL-18 pathway may be another potential mechanism on the decreasing effect of IL-37 on ICAM-1. IL-18 is suppressed by IL-37 through enhancing the effect of IL-18BP, which in turn decreases the expression of ICAM-1 [88]. So far, the exact effect and mechanism of the IL-18 pathway are still not well demonstrated and need a further study to make it clear.

In this study, we finally confirmed that IL-37 which exerts its effect on the ICAM-1 level by reduction of NF-κB phosphorylation has anti-inflammation function upon TLR2 activation in HCAECs. But the inhibition of IL-18 may be another possibility of inhibited effect of IL-37 on ICAM-1 independent on NF-κB phosphorylation. In conclusion, the suppression of the TLR2-NF-κB-ICAM-1 pathway in HCAECs can prominently reduce the development of inflammatory reaction while TLR2 activation can increase ICAM-1 expression [87] (Figure 3). Correspondingly, an experiment in a mouse myocardial ischemia/reperfusion (I/R) injury model has further
demonstrated that IL-37 exerts its anti-inflammatory effect via TLR-4/NF-κB inflammation pathway. In this study, they found that NF-κB activation was suppressed significantly in the IL-37-treated group compared with the untreated group, which is consistent with the results of the reduced production of inflammatory cytokines [89]. Moreover, they also found that TLR-4 expression was inhibited significantly in IL-37-treated I/R mice compared with untreated mice since the inhibition of the inflammation response was due to the decreased expression of TLR-4, an upstream signaling of NF-κB [89]. Finally, they also confirmed that IL-37 could suppress the expression of proinflammatory cytokines such as TNF-α, IL-6, and IL-1β by downregulating TLR-4/NF-κB signaling [90].

3.3. IL-37 Involves in the Adhesion and Transmigration of Neutrophils in HCAECs. Moreover, IL-37 is also associated with the adhesion and transmigration of neutrophils in HCAECs. Neutrophils are not only involved in endothelial cell-mediated inflammatory response but also tended to release inflammatory cytokines expressing proteins and other cytokines to induce the adhesion of other polymorphonuclear cells, so as to further promote inflammation and atherosclerosis progression [91–94]. The endothelial inflammatory response includes the expression of cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) that allow circulating neutrophils to adhere to sites of endothelial injury [95–97], which is involved in the pathogenesis and development of atherosclerosis [98–100]. The recent studies have found that TLR [101, 102] activation can induce endothelial inflammatory responses and then followed by the adhesion and transmigration of the neutrophils [103–106], while this transmigration can be reduced when TLRs are inhibited [107–110]. So some scholars insist that IL-37 can decrease the ICAM-1 expression in HCAECs stimulated with TLR2/4 activation, followed by the reduction of adhesion and transmigration of neutrophils [111–113]. Heretofore, the previous studies have demonstrated that the protective effects of IL-37 are associated with reduced IKK phosphorylation, NF-κB intranuclear translocation, MCP-1 production, and mononuclear cell accumulation in the ischemic myocardium of the mouse coronary microvascular endothelial cells isolated from the IL-37-tg mice. And the similar results have been proved in human aortic valve interstitial cells stimulated with the TLR2/4 agonist. Furthermore, the current research is focus on researching the effect of the adhesion and transmigration of neutrophils in HCAECs to make a further confirmation of this possible mechanism.

Correspondingly, a study which revealed that IL-37 inhibits neutrophil recruitment through modulating chemokine expression in vivo and migration ability in vitro in a mouse myocardial ischemia/reperfusion (I/R) injury model has further demonstrated our hypothesis mentioned above. In this study, they found that IL-37-treated mice showed less infiltration of inflammatory cells, which, as a result of IL-37 treatment, decreased the infiltration of neutrophils significantly after I/R injury compared with the control mice. LIX, as a potent chemoattractant for neutrophil infiltration [114] was obviously suppressed by IL-37, to inhibit the migration of neutrophils in a concentration-dependent manner, which indicated that the in vivo IL-37-mediated inhibition of neutrophils within the ischemic myocardium in I/R mice may be due to their suppressed migration potential and the decreased expression of chemokines [90].

4. Prospects

A large number of studies have confirmed that coronary atherosclerosis (AS) begins as a chronic inflammatory disorder characterized by a condition within the arterial wall in which the accumulation of cells, cholesterol, and extracellular matrix causes the hardening of the arterial wall [115, 116]. In the process of atherosclerosis, macrophage and foam cells accumulated under the blood vessel endothelium cells, especially in the plaque [117]. Proinflammatory and anti-inflammatory cytokines as well as inflammatory cells play a pivotal role in the development of inflammation. Once the balance of proinflammatory and anti-inflammatory cytokines is broke, it can promote the plaque progress and the plaque becomes unstable, which results in clinical acute cardiovascular events [118]. Studies have revealed that the concentration of IL-37 increases significantly in the foam or macrophage cells of the atherosclerotic plaque, suggesting that IL-37 released from the atherosclerotic lesion to the blood may play a protective role in the development of atherosclerosis [119–121]. Predictably, from this perspective, IL-37 may be involved in atherosclerosis-related diseases since it is expressed in the foam-like cells of atherosclerotic coronary and carotid artery plaques. IL-37 induced in an inflammatory context may be associated with the development of atherosclerosis while it plays a vital role in the development of inflammatory reaction through inhibiting the production of inflammatory cytokine mentioned above [74, 122].

From this review, we hypothesize that IL-37 may provide a new therapeutic approach to antagonize or delay the formation of atherosclerosis, to prevent or delay the formation and development of coronary atherosclerotic heart disease or acute coronary syndromes. Thus, it is worth for us to make a further study on the anti-inflammatory mechanism and clinical application of IL-37. However, the formation and progression of the disease are a complex and multifactorial process. Therefore, study and cognition of a single factor for disease intervention and treatment unlikely achieve the desired result. We should focus on more than one factor at the cellular and molecular level to do more study of the disease, in order to make a more comprehensive and systematic cognition to its pathophysiology.

Many cytokines or chemokines are involved in the process of anti-inflammatory reaction in HCAECs. For example, a recent study has illustrated that TNFα and cigarette smoke extract synergise to induce expression of the transcriptional regulator activating transcription factor 3 (ATF3), which is able to decrease inflammatory gene expression independently of the activation of NF-κB in HCAECs. So, the modulation of ATF3 expression may represent a novel approach to modulate proinflammatory gene expression and open new
therapeutic avenues to treat proinflammatory diseases [123]. Besides, the upregulation of microRNA-138/130a could alleviate HCAEC injury and inflammatory response [124, 125]. What is more, amino acids may exhibit anti-inflammatory effects during endothelial inflammation in HCAECs [126].

In short, the intervention for a variety of factors including IL-37 in the inflammatory response of endothelial cells will provide an innovative way of therapeutic potential and strategy in order to give a more comprehensive and systematic treatment of inflammatory diseases such as atherosclerosis.

5. Conclusions

Currently, a growing bodies of research have revealed the view that IL-37 plays a vital role to inhibit various inflammation responses especially in the formation of atherosclerosis in cardiovascular disease. The TLR2-NF-κB-ICAM-1 pathway in HCAECs which could be suppressed by IL-37 expression may be associated with the development of inflammatory reaction. A large amount of data and experiments have confirmed that IL-37 emerges as a possible new therapeutic approach to suppress inflammatory diseases. So how to enhance the effect of IL-37 may be the next study point in the future.

Abbreviations

HCAECs: Human coronary artery endothelial cells  
TLR: Toll-like receptors  
NF-κB: Nuclear transcription factor-κB  
ICAM-1: Intercellular adhesion molecule-1  
VCAM-1: Vascular cell adhesion molecule-1  
MCP-1: Monocyte chemotactic protein-1  
MIP-2: Macrophage inflammatory protein-2  
PMBCs: Peripheral blood mononuclear cells  
AVICs: Aortic valve intecedtial cells  
TGF-β: Transforming growth factor β  
Th17 cells: T helper 17 cells  
Mast cells: MCs  
DCs: Dendritic cells  
IL-37: Interleukin-37  
IL-1R: Interleukin-1 receptor  
IL-1F7: Interleukin-1 family 7  
LPS: Lipopolysaccharide  
IL37-tg: Transgenic mice expressing human interleukin-37  
IL-18BP: Interleukin 18-binding protein  
IL-18Ra, β: Interleukin-18 receptor-α, β  
MyD88: Myeloid differentiation factor 88  
IκB: Inhibitor protein of NF-κB  
IKK: Inhibitor of NF-κB kinase  
TIR-8: Toll/IL-1 receptor-related-8  
TNF-α: Tumor necrosis factor-α  
ATF3: Activating transcription factor 3  
ROS: Reactive oxygen species  
STEMI: ST-segment elevation myocardial infarction  
PCI: Percutaneous coronary intervention  
AS: Atherosclerosis.

Conflicts of Interest

The authors declare that there is no conflicts of interest regarding the publication of this article.

Authors’ Contributions

XY is involved in drawing up the outline, acquisition, and analysis of data and drafted and revised the manuscript. BX participated in the acquisition and integration of data. GW and JL offered the latest progress of experimental data in their present study. DW provided the technical guidance for figure making. XC and JL provided background support by the Natural Science Foundation of Guangdong Province and conducted the revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by the Natural Science Foundation of Guangdong Province grant 2015A030313441.

References

[1] C. Dinarello, W. Arend, J. Sims et al., “IL-1 family nomenclature,” Nature Immunology, vol. 11, no. 11, p. 973, 2010.
[2] C. A. Dinarello, “Introduction to the interleukin-1 family of cytokines and receptors: drivers of innate inflammation and acquired immunity,” Immunological Reviews, vol. 281, no. 1, pp. 5–7, 2018.
[3] C. A. Dinarello, C. Nold-Petry, M. Nold et al., “Suppression of innate inflammation and immunity by interleukin-37,” European Journal of Immunology, vol. 46, no. 5, pp. 1067–1081, 2016.
[4] M. F. Nold, C. A. Nold-Petry, J. A. Zepp, B. E. Palmer, P. Butler, and C. A. Dinarello, “IL-37 is a fundamental inhibitor of innate immunity,” Nature Immunology, vol. 11, no. 11, pp. 1014–1022, 2010.
[5] C. A. Nold-Petry, C. Y. Lo, I. Rudloff et al., “IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction,” Nature Immunology, vol. 16, no. 4, pp. 354–365, 2015.
[6] C. Garlanda, C. A. Dinarello, and A. Mantovani, “The interleukin-1 family: back to the future,” Immunity, vol. 39, no. 6, pp. 1003–1018, 2013.
[7] I. Rudloff, J. Godsell, C. A. Nold-Petry et al., “Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus,” Arthritis & Rheumatology, vol. 67, no. 12, pp. 3219–3225, 2015.
[8] F. L. van de Veerendonk, A. K. Stockman, G. Wu et al., “IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 3001–3005, 2012.
[9] S. J. Busfield, C. A. Comrack, G. Yu et al., “Identification and gene organization of three novel members of the IL-1 family on human chromosome 2,” Genomics, vol. 66, no. 2, pp. 213–216, 2000.
[10] S. Kumar, P. C. McDonnell, R. Lehr et al., “Identification and initial characterization of four novel members of the interleukin-1 family,” *Journal of Biological Chemistry*, vol. 275, no. 14, pp. 10308–10314, 2000.

[11] G. Pan, P. Risser, W. Mao et al., “IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp,” *Cytokine*, vol. 13, no. 1, pp. 1–7, 2001.

[12] S. L. Taylor, B. R. Renshaw, K. E. Garka, D. E. Smith, and J. E. Sims, “Genomic organization of the interleukin-1 locus,” *Genomics*, vol. 79, no. 5, pp. 726–733, 2002.

[13] S. Sharma, N. Kulk, M. F. Nold et al., “The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines,” *The Journal of Immunology*, vol. 180, no. 8, pp. 5477–5482, 2008.

[14] E. N. McMame, J. C. Masterson, P. Jedlicka et al., “Interleukin-37 expression protects mice from colitis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 40, pp. 16711–16716, 2011.

[15] A. M. Bulau, M. Fink, C. Maucksch et al., “In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis,” *ScientificWorldJournal*, vol. 11, pp. 2480–2490, 2011.

[16] N. Sakai, H. L. van Sweringen, R. M. Belizaire et al., “Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells,” *Journal of Gastroenterology and Hepatology*, vol. 27, no. 10, pp. 1609–1616, 2012.

[17] Y. Luo, X. Cai, S. Liu et al., “Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 42, pp. 15178–15183, 2014.

[18] C. J. Henry, M. Casás-Selves, J. Kim et al., “Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors,” *Journal of Clinical Investigation*, vol. 125, no. 12, pp. 4666–4680, 2015.

[19] Q. Zhan and Q. Zeng, “IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells,” *Molecular Medicine*, vol. 23, no. 1, p. 1, 2017.

[20] J. Li, Y. Zhai, L. Ao et al., “Interleukin-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice,” *Cytokine*, vol. 95, pp. 55–63, 2017.

[21] Y. Li, Z. Wang, T. Yu et al., “Increased expression of IL-37 in patients with Graves’ disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells,” *PLoS One*, vol. 9, no. 9, article e107183, 2014.

[22] M. Zeng, W. Dang, B. Chen et al., “IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response,” *Clinical Rheumatology*, vol. 35, no. 9, pp. 2251–2258, 2016.

[23] H. S. Slimani, Z. Yufeng, N. G. Yousif et al., “P504 critical role IL-37 to ameliorate endotoxemic cardiac depression in aging mice: a critical role of suppression cardiodepressant cytokines,” *Cardiovascular Research*, vol. 103, article S92, Supplement 1, 2014.

[24] H. Al Shahi, K. Shimada, K. Miyachi et al., “Elevated circulating levels of inflammatory markers in patients with acute coronary syndrome,” *International Journal of Vascular Medicine*, vol. 2015, Article ID 805375, 8 pages, 2015.

[25] X. Wang, X. Cai, L. Chen, D. Xu, and J. Li, “The evaluation of plasma and leukocytic IL-37 expression in early inflammation in patients with acute ST-segment elevation myocardial infarction after PCI,” *Mediators of Inflammation*, vol. 2015, Article ID 626934, 6 pages, 2015.

[26] G. K. Chalikias, D. N. Tziakas, J. C. Kaski et al., “Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome,” *Atherosclerosis*, vol. 182, no. 1, pp. 135–143, 2005.

[27] A. L. Pasqui, M. di Renzo, G. Bova et al., “Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes,” *Clinical and Experimental Medicine*, vol. 6, no. 1, pp. 38–44, 2006.

[28] A. Caraffa, C. Conti, C. D Ovidio et al., “New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 32, no. 3, pp. 449–454, 2018.

[29] F. Mastrangelo, I. Frydas, G. Ronconi et al., “Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 32, no. 2, pp. 195–198, 2018.

[30] I. Robuffo, E. Toniato, L. Tettamanti et al., “Mast cell in innate immunity mediated by proinflammatory and anti-inflammatory IL-1 family members,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 31, no. 4, pp. 837–842, 2017.

[31] E. Toniato, I. Frydas, I. Robuffo et al., “Activation and inhibition of adaptive immune response mediated by mast cells,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 31, no. 3, pp. 543–548, 2017.

[32] M. F. Nold, C. A. Nold-Petry, C. Lo et al., “187 interleukin 37 employs the IL-1 family inhibitory receptor SIGIRR and the alpha chain of the IL-18 receptor to suppress innate immunity,” *Cytokine*, vol. 63, no. 3, p. 287, 2013.

[33] S. Li, C. P. Neff, K. Barber et al., “Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 112, no. 8, pp. 2497–2502, 2015.

[34] M. Molgora, I. Barajon, A. Mantovani, and C. Garlanda, “Regulatory role of IL-18 in immunity and disease,” *Frontiers in Immunology*, vol. 7, p. 149, 2016.

[35] J. J. O’Shea and P. J. Murray, “Cytokine signaling modules in inflammatory responses,” *Immunity*, vol. 28, no. 4, pp. 477–487, 2008.

[36] M. O. Li, Y. Y. Wan, S. Sanjabi, A. K. L. Robertson, and R. A. Flavell, “Transforming growth factor-β regulation of immune responses,” *Annual Review of Immunology*, vol. 24, no. 1, pp. 99–146, 2006.

[37] S. Sanjabi, L. A. Zenevich, M. Kamanaka, and R. A. Flavell, “Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity,” *Current Opinion in Pharmacology*, vol. 9, no. 4, pp. 447–453, 2009.

[38] P. Rider, Y. Carmi, E. Voronov, and R. N. Apte, “Interleukin-1α,” *Seminars in Immunology*, vol. 25, no. 6, pp. 430–438, 2013.

[39] S. Grimsby, H. Jaensson, A. Dubrovskova, M. Lonnytska, U. Hellman, and S. Souchlenytski, “Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms
a complex with Smad3 and inhibits its transcriptional activity,” *FEBS Letters*, vol. 577, no. 1-2, pp. 93–100, 2004.

[40] A. M. Bulau, M. F. Nold, S. Li et al., “Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 7, pp. 2650–2655, 2014.

[41] I. Cohen, P. Rider, Y. Carmi et al., “Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 6, pp. 2574–2579, 2010.

[42] V. Carriere, L. Roussel, N. Ortega et al., “IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 1, pp. 282–287, 2007.

[43] D. Boraschi, D. Lucchesi, S. Hainzl et al., “IL-37: a new anti-inflammatory cytokine of the IL-1 family,” *European Cytokine Network*, vol. 22, no. 3, pp. 127–147, 2011.

[44] P. Butler, T. Azam, F. Gamboni-Robertson et al., “A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 21, pp. 13723–13728, 2002.

[45] Y. Xie, Y. Li, X. Cai, X. Wang, and J. Li, “Interleukin-37 suppresses ICAM-1 expression in parallel with NF-κB down-regulation following TLR2 activation of human coronary artery endothelial cells,” *International Immunopharmacology*, vol. 38, pp. 26–30, 2016.

[46] P. D. Moon, H. J. Jeong, J. Y. Um, H. M. Kim, and S. H. Hong, “LPS-induced inflammatory cytokine production was inhibited by HyungbanglihwaTang through blockade of NF-κB in peripheral blood mononuclear cells,” *International Journal of Neuroscience*, vol. 117, no. 9, pp. 1315–1329, 2007.

[47] Q. Zhao and F. S. Lee, “Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB in human type II alveolar epithelial cells,” *International Journal of Molecular Medicine*, vol. 38, pp. 26–30, 2016.

[48] T. Kawai and S. Akira, “Signaling to NF-kappaB by Toll-like receptors,” *Trends in Molecular Medicine*, vol. 13, no. 11, pp. 460–469, 2007.

[49] M. H. K. Roshan, A. Tambo, and N. P. Pace, “The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis,” *International Journal of Inflammation*, vol. 2016, Article ID 1532832, 11 pages, 2016.

[50] A. Armoza, Y. Haim, A. Basiri, T. Wolak, and E. Paran, “Tomato extract and the carotenoids lycopene and lutein improve endothelial function and attenuate inflammatory NF-κB signaling in endothelial cells,” *Journal of Hypertension*, vol. 31, no. 3, pp. 521–529, 2013.

[51] C. A. Dinarello and P. Butler, “Interleukin-37,” *Seminars in Immunology*, vol. 25, no. 6, pp. 466–468, 2013.

[52] C. A. Dinarello, D. Novick, S. Kim, and G. Kaplan, “Interleukin-18 and IL-18 binding protein,” *Frontiers in Immunology*, vol. 4, p. 289, 2013.

[53] G. Kaplan, “Interleukin-18: biological properties and role in disease pathogenesis,” *Immunological Reviews*, vol. 281, no. 1, pp. 138–153, 2018.

[54] S. Kumar, C. R. Hanning, M. R. Brigham-Burke et al., “Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production,” *Cytokine*, vol. 18, no. 2, pp. 61–71, 2002.

[55] N. Festjens, S. Cornelis, M. Lamkanfi, and P. Vandenabeele, “Caspase-containing complexes in the regulation of cell death and inflammation,” *Biological Chemistry*, vol. 387, no. 8, pp. 1005–1016, 2006.

[56] C. A. Dinarello, “Novel targets for interleukin 18 binding protein,” *Annals of the Rheumatic Diseases*, vol. 60, Supplement 3, pp. iii18–iii24, 2001.

[57] H. M. Chen and M. Fujita, “IL-37: a new player in immune tolerance,” *Cytokine*, vol. 72, no. 1, pp. 113–114, 2015.

[58] K. Bulek, S. Swaidani, J. Qin et al., “The essential role of single Ig IL-1 receptor-related molecule/Toll-IL-1R8 in regulation of Th2 immune response,” *The Journal of Immunology*, vol. 182, no. 5, pp. 2601–2609, 2009.

[59] I. Rudloff, S. X. Cho, J. C. Lao et al., “Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells,” *Journal of Leukocyte Biology*, vol. 101, no. 4, pp. 901–911, 2017.

[60] R. Smithrithhee, F. Niyonsaba, C. Kiatsurayanon et al., “Human β-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes,” *Journal of Dermatological Science*, vol. 77, no. 1, pp. 46–53, 2015.

[61] Z. Huang, G. W. Zhao, C. H. Gao et al., “Mannose-capped lipoarabinomannan from Mycobacterium tuberculosis induces IL-37 production via upregulating ERK1/2 and p38 in human type II alveolar epithelial cells,” *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 5, pp. 7279–7287, 2015.

[62] P. Butler, F. Gamboni-Robertson, T. Azam, S. H. Kim, and C. A. Dinarello, “Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide,” *Biochemical Journal*, vol. 381, no. 2, pp. 503–510, 2004.

[63] P. W. Zhao, W. G. Jiang, L. Wang, Z. Y. Jiang, Y. X. Shan, and Y. F. Jiang, “Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis,” *PLoS One*, vol. 9, no. 5, article e95346, 2014.

[64] L. Ye, L. Ji, Z. Wen et al., “IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity,” *Journal of Translational Medicine*, vol. 12, no. 1, p. 69, 2014.

[65] J. H. Southcombe, C. W. G. Redman, I. L. Sargent, and I. Granne, “Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia,” *Clinical & Experimental Immunology*, vol. 490, 2015.

[66] L. Xia, H. Shen, and J. Lu, “Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines,” *Cytokine*, vol. 76, no. 2, pp. 553–557, 2015.

[67] W. Liu, L. Deng, Y. Chen et al., “Anti-inflammatory effect of IL-37b in children with allergic rhinitis,” *Mediators of Inflammation*, vol. 2014, Article ID 746846, 13 pages, 2014.

[68] Y. Yang, Z. X. Zhang, D. Lian, A. Haig, R. N. Bhattacharjee, and A. M. Jevnikar, “IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and...
renal ischemia-reperfusion injury,” *Kidney International*, vol. 87, no. 2, pp. 396–408, 2015.

[69] R. Charrad, A. Berraïes, B. Hamdi, J. Ammar, K. Hamzaoui, and A. Hamzaoui, “Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL-17A,” *Immunobiology*, vol. 221, no. 2, pp. 182–187, 2016.

[70] M. Coll-Miró, I. Francos-Quijorna, E. Santos-Nogueira et al., “Beneficial effects of IL-37 after spinal cord injury in mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 5, pp. 1411–1416, 2016.

[71] Q. Ji, Q. Zeng, Y. Huang et al., “Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome,” *Mediators of Inflammation*, vol. 2014, Article ID 165742, 9 pages, 2014.

[72] X. Teng, Z. Hu, X. Wei et al., “IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production,” *The Journal of Immunology*, vol. 192, no. 4, pp. 1815–1823, 2014.

[73] X. Tang, Z. Hu, X. Wei et al., “Effects of interleukin-37 on cardiac function after myocardial infarction in mice,” *International Journal of Clinical and Experimental Pathology*, vol. 8, no. 5, pp. 5247–5251, 2015.

[74] M. Fernández-Velasco, P. Prieto, V. Terrón et al., “NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis,” *PLoS One*, vol. 7, no. 9, article e45260, 2012.

[75] W. S. HU, Y. M. Lin, T. J. Ho et al., “Genistein suppresses the isoproterenol-treated H9c2 cardiomyoblast cell apoptosis associated with P-38, Erk1/2, JNK, and NFκB signaling protein activation,” *The American Journal of Chinese Medicine*, vol. 41, no. 5, pp. 1125–1136, 2013.

[76] A. Jenke, S. Wilk, W. Poller et al., “Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury,” *Cardiovascular Research*, vol. 99, no. 3, pp. 422–431, 2013.

[77] M. Zeng, X. Wei, Z. Wu et al., “NF-κB-mediated induction of autophagy in cardiac ischemia/reperfusion injury,” *Biochemical and Biophysical Research Communications*, vol. 436, no. 2, pp. 180–185, 2013.

[78] S. Zhang, X. Liu, S. Goldstein et al., “Role of the JAK/STAT signaling pathway in the pathogenesis of acute myocardial infarction in rats and its effect on NF-κB expression,” *Molecular Medicine Reports*, vol. 7, no. 1, pp. 93–98, 2013.

[79] X. Q. Zhang, R. Tang, L. Li et al., “Cardiomyocyte-specific p65 NF-κB deletion protects the injured heart by preservation of calcium handling,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 305, no. 7, pp. H1089–H1097, 2013.

[80] J. Yu, Y. Lu, Y. Li et al., “Role of S100A1 in hypoxia-induced inflammatory response in cardiomyocytes via TLR4/Ros/NF-κB pathway,” *Journal of Pharmacy and Pharmacology*, vol. 67, no. 9, pp. 1240–1250, 2015.

[81] D. Rohde, C. Schon, M. Boerries et al., “S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4,” *EMBO Molecular Medicine*, vol. 6, no. 6, pp. 778–794, 2014.

[82] A. Sen, S. Ren, C. Lerchenmüller et al., “MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1,” *PLoS One*, vol. 8, no. 11, article e78684, 2013.

[83] Q. Zhan, R. Song, F. Li et al., “Double-stranded RNA upregulates the expression of inflammatory mediators in human aortic valve cells through the TLR3-TRIF-noncanonical NF-κB pathway,” *American Journal of Physiology-Cell Physiology*, vol. 312, no. 4, pp. C407–C417, 2017.

[84] Q. Zeng, R. Song, D. A. Fullerton et al., “Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 114, no. 7, pp. 1631–1636, 2017.

[85] X. Yang, D. A. Fullerton, X. Su, L. Ao, J. C. Cleveland Jr, and X. Meng, “Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2,” *Journal of the American College of Cardiology*, vol. 53, no. 6, pp. 491–500, 2009.

[86] Q. Zeng, C. Jin, L. Ao et al., “Cross-talk between the Toll-like receptor 4 and Notch1 pathways augments the inflammatory response in the interstitial cells of stenotic human aortic valves,” *Circulation*, vol. 126, 11_Supplement_1, pp. S222–S230, 2012.

[87] J. Li, C. Jin, J. C. Cleveland et al., “Enhanced inflammatory responses to toll-like receptor 2/4 stimulation in type 1 diabetic coronary artery endothelial cells: the effect of insulin,” *Cardiovascular Diabetology*, vol. 9, no. 1, p. 90, 2010.

[88] W. Q. Wang, K. Dong, L. Zhou et al., “IL-37 gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis mice,” *Acta Pharmacologica Sinica*, vol. 36, no. 11, pp. 1377–1387, 2015.

[89] F. Arslan, D. P. de Klein, and G. Pasterkamp, “Innate immune signaling in cardiac ischemia,” *Nature Reviews Cardiology*, vol. 8, no. 5, pp. 292–300, 2011.

[90] B. Wu, K. Meng, Q. Ji et al., “Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice,” *Clinical and Experimental Immunology*, vol. 176, no. 3, pp. 438–451, 2014.

[91] S. Wantha, J. E. Alard, R. T. A. Megens et al., “Neutrophil-derived cathelicidin promotes adhesion of classical monocytes,” *Circulation Research*, vol. 112, no. 5, pp. 792–801, 2013.

[92] O. Soehnlein, L. Lindbom, and C. Weber, “Mechanisms underlying neutrophil-mediated monocyte recruitment,” *Blood*, vol. 114, no. 21, pp. 4613–4623, 2009.

[93] V. Kumar and A. Sharma, “Neutrophils: Cinderella of innate immune system,” *International Immunopharmacology*, vol. 10, no. 11, pp. 1325–1334, 2010.

[94] O. Soehnlein, C. Weber, and L. Lindbom, “Neutrophil granule proteins tune monocyte cell function,” *Trends in Immunology*, vol. 30, no. 11, pp. 538–546, 2009.

[95] M. V. Badiwala, D. Guha, L. Tumiati et al., “Epidermal growth factor-like domain 7 is a novel inhibitor of neutrophil adhesion to coronary artery endothelial cells injured by calcineurin inhibition,” *Circulation*, vol. 124, 11_Supplement_1, pp. S197–S203, 2011.

[96] K. Ley, C. Laudanna, M. I. Cybulsky, and S. Noursargh, “Getting to the site of inflammation: the leukocyte adhesion cascade updated,” *Nature Reviews Immunology*, vol. 7, no. 9, pp. 678–689, 2007.

[97] K. M. Stroka, I. Levitan, and H. Aranda-Espinoza, “OxLDL and substrate stiffness promote neutrophil transmigration by enhanced endothelial cell contractility and ICAM-1,” *Journal of Biomechanics*, vol. 45, no. 10, pp. 1828–1834, 2012.
H. Omi, N. Okayama, M. Shimizu et al., “Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines,” *Journal of Diabetes and its Complications*, vol. 16, no. 3, pp. 201–208, 2002.

H. Omi, N. Okayama, M. Shimizu et al., “Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide,” *Microvascular Research*, vol. 65, no. 2, pp. 118–124, 2003.

H. Omi, N. Okayama, M. Shimizu et al., “Statins inhibit high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production,” *Microvascular Research*, vol. 68, no. 2, pp. 119–125, 2004.

S. Akira and K. Takeda, “Toll-like receptor signalling,” *Nature Reviews Immunology*, vol. 4, no. 7, pp. 499–511, 2004.

T. Kaisho and S. Akira, “Toll-like receptor function and signaling,” *Journal of Allergy and Clinical Immunology*, vol. 117, no. 5, pp. 979–987, 2006.

Q. Lin, M. Li, D. Fang, J. Fang, and S. B. Su, “The essential roles of Toll-like receptor signaling pathways in sterile inflammatory diseases,” *International Immunopharmacology*, vol. 11, no. 10, pp. 1422–1432, 2011.

M. Shinhara, K. I. Hirata, T. Yamashita et al., “Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 27, no. 11, pp. 2384–2391, 2007.

J. E. Cole, A. T. Mitra, and C. Monaco, “Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets,” *Expert Review of Cardiovascular Therapy*, vol. 8, no. 11, pp. 1619–1635, 2010.

K. Wilhelmsen, R. M. Mesa, A. Prakash, F. Xu, and J. Hellman, “Activation of endothelial TLR2 by bacterial lipoprotein upregulates proteins specific for the neutrophil response,” *Innate Immunity*, vol. 18, no. 4, pp. 602–616, 2012.

A. M. Piccinini and K. S. Midwood, “DAMPening inflammation by modulating TLR signalling,” *Mediators of Inflammation*, vol. 2010, Article ID 672395, 21 pages, 2010.

Y. Fang and J. Hu, “Toll-like receptor and its roles in myocardial ischemic/reperfusion injury,” *Medical Science Monitor*, vol. 17, no. 4, pp. Ra100–Ra109, 2011.

H. Bjorkbacka, “Multiple roles of Toll-like receptor signaling in atherosclerosis,” *Current Opinion in Lipidology*, vol. 17, no. 5, pp. 527–533, 2006.

J. S. Lefèvre, S. Marleau, V. Milot et al., “Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B4 and platelet-activating factor,” *The FASEB Journal*, vol. 24, no. 2, pp. 637–647, 2010.

C. V. Carman and T. A. Springer, “A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them,” *The Journal of Cell Biology*, vol. 167, no. 2, pp. 377–388, 2004.

W. A. Muller, “Mechanisms of leukocyte transendothelial migration,” *Annual Review of Pathology*, vol. 6, no. 1, pp. 323–344, 2011.

A. Rahman and F. Fazal, “Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration,” *Antioxidants & Redox Signaling*, vol. 11, no. 4, pp. 823–839, 2009.

N. G. Frangogiannis, “Chemokines in ischemia and reperfusion,” *Thrombosis and Haemostasis*, vol. 97, no. 5, pp. 738–747, 2007.

J. Hong, D. J. Maron, T. Shirai, and C. M. Weyand, “Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions,” *International Journal of Clinical Rheumatology*, vol. 10, no. 5, pp. 365–381, 2015.

C. Monaco, S. M. Gregan, T. J. Navin, B. M. J. Foxwell, A. H. Davies, and M. Feldmann, “Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis,” *Circulation*, vol. 120, no. 24, pp. 2462–2469, 2009.

V. Z. Lankin and A. K. Tikhaze, “Role of oxidative stress in the genesis of atherosclerosis and diabetes mellitus: a personal look back on 50 years of research,” *Current Aging Science*, vol. 10, no. 1, pp. 18–25, 2017.

M. Stefla, “Lipids and acute coronary syndromes,” *Vnitrni lekarstvi*, vol. 46, no. 9, pp. 520–525, 2000.

J. Huang, F. L. Hou, A. Y. Zhang, and Z. L. Li, “Protective effect of the polarity of macrophages regulated by IL-37 on atherosclerosis,” *Genetics and Molecular Research*, vol. 15, no. 2, 2016.

C. Shaoyuan, D. Ming, H. Yulang, and F. Hongcheng, “Increased IL-37 in atherosclerotic disease could be suppressed by atorvastatin therapy,” *Scandinavian Journal of Immunology*, vol. 82, no. 4, pp. 328–336, 2015.

B. W. Wu, Q. T. Zeng, K. Meng, and Q. W. Ji, “The potential role of IL-37 in atherosclerosis,” *Pharmazie*, vol. 68, no. 11, pp. 857–860, 2013.

S. McCurdy, C. A. Liu, J. Yap, and W. A. Boisvert, “Potential role of IL-37 in atherosclerosis,” *Cytokine*, 2017, In press.

J. E. Teasdale, G. G. J. Hazell, A. M. G. Peachey et al., “Cigarette smoke extract profoundly suppresses TNFα-mediated proinflammatory gene expression through upregulation of ATF3 in human coronary artery endothelial cells,” *Scientific Reports*, vol. 7, no. 1, article 39945, 2017.

J. B. Li, H. Y. Wang, Y. Yao et al., “Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway,” *Journal of Cellular and Molecular Medicine*, vol. 21, no. 8, pp. 1482–1491, 2017.

C. L. Song, B. Liu, Y. F. Shi et al., “MicroRNA-130a alleviates human coronary artery endothelial cell injury and inflammatory responses by targeting PTEN via activating PI3K/Akt/eNOS signaling pathway,” *Oncotarget*, vol. 7, no. 44, pp. 71922–71936, 2016.

S. Hasegawa, T. Ichiyama, I. Sonaka et al., “Cysteine, histidine and glycine exhibit anti-inflammatory effects in human coronary arterial endothelial cells,” *Clinical and Experimental Immunology*, vol. 167, no. 2, pp. 269–274, 2012.